Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

John Deanfield, CBE | Image Credit: University College London

Semaglutide’s cardioprotective effects may be independent of baseline adiposity and weight loss based on data from the recent SELECT trial of patients with 

atherosclerotic cardiovascular disease (ASCVD)

, indicating a possible benefit beyond adiposity reduction.

 is a well-known risk factor for cardiovascular morbidity and mortality, standard measurements such as weight and body mass index are insufficient to determine exact adiposity levels. Often, they fail to distinguish between visceral and subcutaneous fat, both of which may have distinct implications for cardiovascular risk. Additionally, ectopic fat deposits, such as epicardial and perivascular fat, may exert local pathogenic effects on the heart or blood vessels.

“These analyses aim to assist practitioners with patient selection, provide clinically relevant adiposity characteristics for treatment response, advance understanding of mechanisms for benefit, and inform healthcare policy decisions,” John Deanfield, CBE, professor of cardiology at University College London and director of the National Institute for Cardiovascular Outcomes Research, and colleagues wrote. “Such insights are crucial, as they could help reconceptualize GLP-1 RAs from primarily weight-loss medications to disease-modifying treatments with broader therapeutic applications.”

The SELECT trial was a randomized, double-blind, multicenter, placebo-controlled, event-driven phase 3 trial, evaluating whether once-weekly subcutaneous semaglutide 2.4 mg was superior to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and overweight or obesity, but without diabetes. The trial included 804 sites across 41 countries.

Patients were eligible for the study if they were aged ≥45 years, had a body mass index (BMI) of 27 kg/m2 or above, and had established ASCVD, which was defined as ≥1 among previous myocardial infarction, 

, or symptomatic peripheral artery disease. Patients were excluded if they exhibited glycated hemoglobin (HbA1c) of ≥48 mmol/mol, a history of 

, or previous myocardial infarction, stroke, or transient ischemic attack.

Deanfield and colleagues randomly assigned a total of 17,604 patients in a 1:1 ratio to either semaglutide or placebo. Patients were then followed up for MACE, adverse events, and other events for an average of 39.8 months (standard deviation [SD] 9.4). In total, 17,061 patients (96.9%) completed the trial, either by attending the follow-up visit or dying.

Across BMI categories, investigators found an increase in prediabetes prevalence and blood pressure. Inflammatory burden also substantially increased from 36.4% in the 1827 patients in the lowest BMI category to 72% among the 1268 patients in the highest category. Mean duration of exposure was 33.3 months (SD 14.4) for semaglutide and 35.1 months (13) for placebo, with permanent premature discontinuation occurring in 2351 of 8803 patients and 2078 of 8801 patients assigned to semaglutide and placebo, respectively.

Semaglutide also substantially reduced MACE incidence across all baseline weight and waist circumference categories. Analyses for linear trends showed lower baseline measurements were associated with lower incidence, with an average of 4% reduction in risk per 5 kg lower bodyweight (HR, 0.96; 95% CI, 0.94-0.99; 

 = .001) and per 5 cm smaller waist circumference (HR, 0.96; 95% CI, 0.93-0.99; 

 = .004). Investigators estimated 33% of the observed benefit on MACE was mediated through waist circumference reduction (HR, 0.86; 95% CI, 0.77-0.97 after adjustment for time-varying changes in waist circumference).

“This supports the reconceptualization of GLP-1 RAs as potential cardiovascular disease-modifying agents, with implications for clinical practice and health-care policy,” Deanfield and colleagues wrote.

Deanfield J, Michael Lincoff A, Kahn S, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. 

. 2025;1-12 https://doi.org/10.1016/S0140-6736(25)01375-3

Sattar N, Presslie C, Rutter MK, McGuire DK. Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity. Diabetes Care. 2024;47(4):531-543. 

Articles

Semaglutide's cardioprotective effects may extend beyond weight loss, as suggested by the SELECT trial involving patients with atherosclerotic cardiovascular disease (ASCVD). The trial demonstrated that semaglutide significantly reduced major adverse cardiovascular events (MACE) across various baseline weight and waist circumference categories. The study included 17,604 patients, with a follow-up period averaging 39.8 months. Results indicated a 4% risk reduction in MACE per 5 kg lower body weight and per 5 cm smaller waist circumference. These findings suggest GLP-1 receptor agonists could be redefined as cardiovascular disease-modifying agents.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

SELECT: Semaglutide Indicates Possible Cardiovascular Disease-Modifying Effect

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The United States Food and Drug Administration (FDA) announced the first 9 voucher recipients under its new Commissioner’s National Priority Voucher (CNPV) pilot program, designed to accelerate review timelines for drugs and biologics that address major national priorities on October 16.

 The program aims to encourage innovation in areas such as unmet medical need, public health crises, domestic drug manufacturing, and medication affordability.

The FDA described the initiative as a modernization of the review process that combines expedited timelines with enhanced communication between sponsors and review teams. Under the CNPV pilot, recipients will receive a regulatory decision within 1–2 months of filing a complete application, along with increased interaction with FDA scientists during development and review. If necessary, the agency may extend review time in cases of incomplete submissions or manufacturing violations.

“The goal is to deliver more cures and meaningful treatments—especially ones that have an outsized impact on our most pressing national priorities,” said FDA Commissioner Marty Makary, MD, MPH, in a statement.

 “We must modernize the review process and try new approaches to meet the needs of the American people.”

"This drug would directly compete against a much more expensive option that currently has a monopoly in the American market, and this will bring down costs very significantly," President Donald Trump said about Pergoveris' voucher during the Improving Fertility Care and Expanding Access to IVF for Americans news conference also held on the 16th.

The FDA noted that the new process reduces the traditional 10–12 month review timeline through a concurrent, team-based evaluation involving physicians and scientists. Once all review components are complete, applications will undergo a final “tumor board–style” meeting to ensure a comprehensive multidisciplinary assessment.

The agency expects to announce additional CNPV recipients in the coming months as it continues to refine and expand the program.

Each FDA drug review division nominated 1 product for inclusion in the CNPV program, with additional applications accepted through direct sponsor submissions. The first 9 recipients include:

Follitropin Alfa + Lutropin Alfa (Pergoveris)
Company: EMD Serono (Merck KGaA)
Indication: Infertility
Background Info:

Follitropin alfa + lutropin alfa is a recombinant gonadotropin approved in multiple countries for ovulation induction; its selection for the CNPV pilot reflects a strategic push to broaden access and lower costs of fertility therapies in the US.

Teplizumab (Tzield)
Company: Sanofi
Indication: Type 1 Diabetes 

A humanized anti-CD3 monoclonal antibody, teplizumab is FDA-approved to delay the onset of stage 3 type 1 diabetes in adults and children aged ≥8 years with stage 2 disease; its CNPV award underscores its potential to address a major unmet autoimmune disease.

Cytisinicline 
Company: Achieve Life Sciences
Indication: Nicotine/vaping dependence

Cytisinicline is an investigational oral nicotinic receptor partial agonist that has received FDA Breakthrough Therapy Designation for e-cigarette (vaping) and nicotine dependence; its CNPV selection aligns with efforts to curb the rising public-health burden of vaping.

 mutation–related congenital hearing loss, DB-OTO has demonstrated meaningful hearing improvements in children and is now in phase 1/2 development; its CNPV designation reflects a major national priority in rare-disease gene therapy.

Cenegermin-bkbj (Oxervate)
Company: Dompé
Indication: Blindness

Cenegermin-bkbj is a recombinant human nerve growth factor approved for neurotrophic keratitis; though its current use addresses a rare ocular disease, its CNPV award signals broader potential in regenerative ophthalmology and prioritized therapies.

RMC-6236 
Company:
Indication: Pancreatic cancer

RMC-6236 is a novel orally-active RAS(ON) inhibitor in phase 3 for metastatic pancreatic ductal adenocarcinoma; early data show antitumor activity and acceptable safety, making it a high-priority candidate under the CNPV scheme.

Bitopertin 
Company: Disc Medicine
Indication: Porphyria

Bitopertin is an investigational oral glycine transporter 1 inhibitor targeting erythropoietic protoporphyria and X-linked protoporphyria; although a phase 2 study met the primary biomarker endpoint and missed a secondary, its CNPV selection points to unmet need in rare metabolic disorders.

Ketamine
Company: Phlow
Indication: Domestic manufacturing of anesthetic

Ketamine, a decades-old anesthetic agent and Schedule III substance, has been awarded a CNPV to incentivize US domestic manufacturing of this essential medicine, not specific to a new indication but to strengthen critical drug supply security.

Amoxicillin and Clavulanate Potassium (Augmentin XR)
Company: USAntibiotics
Indication: Domestic manufacturing of antibiotic

Augmentin XR is an FDA-approved extended-release combination antibiotic used to treat community-acquired pneumonia and acute bacterial sinusitis. The drug is produced by USAntibiotics at its Bristol, Tennessee facility—the nation’s only remaining source of US-made amoxicillin products—and received a voucher  to encourage domestic manufacturing of critical antibiotics.

1. FDA Awards First-Ever National Priority Vouchers to Nine Sponsors. News release. FDA. October 16, 2025. https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors
2. EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies. News release. EMD Serono. Published October 16, 2025. Accessed October 22, 2025. https://www.emdserono.com/us-en/company/news/press-releases/agreement-with-u-s-government-to-expand-access-to-ivf-therapies-16-10-2025.html
3. Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. 

. 2023;46(10):1848-1856. doi: 10.2337/dc23-0675
4. Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence. News release. Achieve Life Sciences. Published July 31, 2024. Accessed October 22, 2025. https://ir.achievelifesciences.com/news-events/press-releases/detail/204/achieve-life-sciences-announces-fda-grants-breakthrough-therapy-designation-to-cytisinicline-for-the-treatment-of-e-cigarette-or-vaping-nicotine-dependence?
5. Valayannopoulos V, Bance M, Carvalho DS, et al. DB-OTO Gene Therapy for Inherited Deafness. 

. Published online October 12, 2025. doi: 10.1056/nejmoa2400521
6. NEUROTROPHIC KERATITIS. Dompe.com. Published 2018. Accessed October 22, 2025. https://www.dompe.com/us/therapeutic-areas/ophthalmics/neurotrophic-keratitis/
7. Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). NIH National Cancer Institute. Published 2016. Accessed October 22, 2025. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-08850&utm
8. Ducamp S, Wu M, Putra J, et al. The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria. 

. Published online July 15, 2025. doi: 10.1172/jci181875
9. Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America - Phlow. News release. Phlow. Published October 16, 2025. Accessed October 22, 2025. https://www.phlow-usa.com/phlow-corp-selected-by-the-u-s-food-and-drug-administration-commissioners-first-ever-national-priority-voucher-pilot-program-to-advance-manufacturing-of-a-critical-essential-medicine-in-ame/?utm
10. USAntibiotics Awarded FDA National Priority Voucher for Domestic Manufacturing of Critical Antibiotic. News release. USAntibiotics. October 22, 2025. https://www.businesswire.com/news/home/20251022201831/en/USAntibiotics-Awarded-FDA-National-Priority-Voucher-for-Domestic-Manufacturing-of-Critical-Antibiotic

The FDA has launched the Commissioner's National Priority Voucher (CNPV) pilot program to expedite drug and biologic reviews addressing key national priorities. This initiative aims to modernize the review process, reducing timelines from 10-12 months to 1-2 months, and enhancing communication between sponsors and FDA scientists. The first nine recipients include drugs targeting infertility, type 1 diabetes, nicotine dependence, deafness, blindness, pancreatic cancer, porphyria, and domestic manufacturing of anesthetics and antibiotics. The program seeks to foster innovation, address unmet medical needs, and improve medication affordability and accessibility.

FDA launches the Commissioner’s National Priority Voucher program, expediting drug reviews for critical health needs.

FDA News

Type 1 Diabetes

Inside the FDA’s New Voucher Program: First 9 Picks Target Diabetes to Vaping

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD

American College of Chest Physicians (CHEST) Annual Meeting

, the topic of biologic therapy seems to grow in frequency and significance — correlative with the burgeoning drug class itself, which has become a staple regimen in severe cases of most 

Though biologic conversations still lean toward forward-looking, pulmonary medicine has reached a time when they are very present and accessible for their drug class. The fun part is speculation; the important part is implementation.

 during CHEST 2025 in Chicago, IL, this week, Sara Assaf, MD, assistant professor of pulmonary and critical care at the University of New Mexico School of Medicine, discussed her presentation titled, “How Do I Do It? Selecting the Right Biologic for the Right Patient with Severe Asthma.”

Assaf shared insights into her own practice’s strategies to prescribe, monitor, and assess biologic therapies in their patients with asthma. She also discussed how the rapidly developing industry of biologic therapy research and development has refined asthma care strategy, and where there remains some misunderstandings about this emerging drug class between her colleagues and patients.

The interview transcript was lightly edited for clarity.

 When we talk about selecting the right biologic for the right patient, where does that start?

 Yeah, it's a great question. I think you have to take into consideration both the biologic and the patient, because factors at the level of the patients will come into play — like how much they exacerbate. Are they needing any systemic corticosteroids? What are their asthma scores, their quality of life, their spirometry? But you also have the biologic factors — things that are more related to biomarkers or phenotype that each biologic may address differently. Sometimes the dosing frequency of biologics can be a criterion to choose one over the other. Insurance costs [matter]. And patients can also be part of that decision making to decide if any biologic could be applicable for them, which one would be their preference.

: How has competition in biologic drug class development shifted their role and priority in airway disease?

I think as we have more options and as we learn more about it — and as we also know that you can have asthma with other concomitant comorbidities or conditions that a lot of those biologics are also approved for — we're gaining a better understanding or approach for which ones would fit better patients, depending on their clinical traits, their biomarkers, and their comorbidities.

So yes, we have more options, but those options can serve different purposes. Although they're all under type 2 inflammation, there are some nuances — and they're also ones that are not used for type 2 inflammation. So those options, maybe they're allowing for more targeted choices, depending on the patient characteristics, the comorbidities, and other factors, as we talked about.

: What is your own prescribing strategy with patients who may benefit from biologic therapy?

 When we have our severe asthma patients in clinic, we try to phenotype them. We try to see what biomarkers they have predominantly — is it eosinophilia? Is it FeNO [fractional exhaled nitric oxide]? Are there any other factors?

I tend to make sure they're adherent to their inhaler regimen, and then try to see if there are any other comorbid conditions. Recently, I had someone with eosinophilic esophagitis. In that specific case, we were more directed towards anti-IL-4 [interleukin 4] receptor antagonist [biologics].

I think each case is different, and understanding the different clinical characteristics and trying to evaluate for what potential endotype and other factors helps us more with that algorithm or approach. But in a lot of cases, they might overlap, and you might still end up with multiple options that could be reasonable to offer for patients.

With which patients are we still not achieving the clinical benefit we potentially could with biologics?

Of course, the low type 2 [inflammation patinets] has always been where we're trying to better understand [disease mechanism]. Now we have options. We have the anti-TSLP [tezepelumab] and I think maybe more to come as well. And sometimes, if they don't have the type 2 inflammatory markers, the steroid-dependent anti-IL-4 biologics can be also used. These are some of the patients that we need to better understand. And of course, the ones that already started on a biologic and don't necessarily respond well — [how are we] switching mechanisms and what class to switch to sometimes could be challenging to do.

What are the most common misconceptions of biologic therapy you see among your colleagues?

I think one of the misconceptions — mostly at the level of patients and not my colleagues — is that once that you start [biologics], you can remove your inhaler therapy. [They think] that it's going to be a curative, and you don't need to take your inhalers anymore. That's something that we keep on stressing in clinics that once we're using this add-on therapy, that does not mean that you're not going to continue taking your daily regimen with inhaled steroid and any other controller.

And one of the important concepts that I think we also discussed in our session was remission, and that's something that we're learning more about. It's yet for us to understand once patients are doing better on biologics, what to step down as therapy — the biologic, the inhaler, none, or both. So, there’s more to learn from that perspective.

Videos

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Dupilumab (Dupixent) provided greater improvement in both large and small airway function outcomes than omalizumab (Xolair) in patients with 

chronic rhinosinusitis with nasal polyps (CRSwNP)

American College of Chest Physicians (CHEST) 2025 Annual Meeting

The findings from the phase 4 EVEREST trial, presented during late-breaking sessions at the annual meeting, showed distinct efficacy outcomes in the 2 biologics as it relates to physiological approaches to improve asthma control and reduce exacerbations among patients with coexisting CRSwNP.

Investigators led by New York-based allergist John Oppenheimer, MD, sought to report additional lung function parameters derived from EVEREST. The original global, multicenter, randomized, active-controlled analysis was among the first head-to-head trials comparing a pair of biologic therapies with unique pathway-targeting mechanisms across a large group of participants with CRSwNP. 

The original findings showed dupilumab was significantly superior to omalizumab in improvements to patients’ nasal polyp scores and University of Pennsylvania Smell Identification Test (UPSIT) at 24 weeks.

Investigators additionally observed improved forced expiratory volume in 1 second (FEV

) by 153 mL among patients receiving dupilumab (95% CI, 52 – 255), indicating benefit to large airway function.

The fully human monoclonal antibody dupilumab inhibits interleukin 4 and 13 (IL-4; IL-13), the primary drivers of type 2 inflammation across multiple diseases; omalizumab reduces inflammation by targeting immunoglobulin E (IgE).

“Type 2 inflammation often drives the pathophysiology of both CRSwNP and asthma,” investigators wrote. “Patients with CRSwNP who have coexisting asthma are likely to have greater disease severity and higher overall disease burden. Here, we report the efficacy of dupilumab vs omalizumab for additional lung function parameters in EVEREST.”

What was the assessment design for EVEREST?

EVEREST included patients ≥18 years old with severe CRSwNP and coexisting uncontrolled asthma. Participants were randomized 1:1 to background mometasone furoate nasal spray and either add-on 300 mg dupilumab once every 2 weeks or 75 – 600 mg omalizuab every 2 – 4 weeks, for 24 weeks.

Oppenheimer and colleagues sought change from baseline in pre-bronchodilator forced expiratory flow (FEF) at 25 – 75% capacity — indicating small airway function — and forced vital capacity (FVC) — indicating air trapping — at weeks 12 and 24 for each treatment arm.

The total observed trial population included 181 participants receiving dupilumab and 179 receiving omalizumab. Dupilumab significantly improved pre-bronchodilator FEF capacity versus omalizumab at week 12 (least squares mean difference, 209 mL/s; 95% CI,65 – 352), and improvements were sustained through week 24 (199 mL/s; 95% CI, 42 – 357).

Investigators additionally observed significantly improved FVC in the dupilumab arm versus omalizumab arm at 12 weeks (174 mL; 95% CI, 76 – 272) and 24 weeks (185 mL; 95% CI, 73 – 298).

Dupilumab provides greater improvement than omalizumab for large and small airway lung function outcomes in patients with CRSwNP and uncontrolled coexisting asthma, which can be a surrogate for improved asthma control and reduced risk for exacerbations,” investigators concluded. “These results may aid physicians in selecting appropriate biologic therapy for patients with CRSwNP and uncontrolled asthma.”

Oppenheimer J, Canonica GW, Peters AT, Lipworth B, et al. Dupilumab vs Omalizumab: Greater Lung Function Improvements in Patients with Chronic Rhinosinusitis with Nasal Polyps and Uncontrolled Asthma (EVEREST) with Dupilumab. Poster presented at: CHEST Annual Meeting 2025. Chicago, IL. October 19 – 22, 2025.

De Corso E, Canonica GW, Heffler E, et al. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. Lancet Respir Med. Published online September 28, 2025. doi:10.1016/S2213-2600(25)00287-5

Dupilumab demonstrated superior efficacy over omalizumab in improving both large and small airway functions in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and uncontrolled asthma, according to the phase 4 EVEREST trial. The trial, presented at the CHEST 2025 Annual Meeting, highlighted dupilumab's significant improvements in nasal polyp scores, smell identification, and lung function parameters such as FEV1, FEF, and FVC. These findings suggest dupilumab may offer better asthma control and reduced exacerbation risk, aiding clinicians in selecting appropriate biologic therapies for these patients.

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

Dupilumab Bests Omalizumab in Airway Improvement for Patients with CRSwNP and Asthma

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

2025 Fall Clinical Dermatology Conference

 will convene in Las Vegas, Nevada, from October 23–26, 2025, bringing together leaders in medical, aesthetic, and surgical dermatology to present recent data and clinical pearls for everyday practice. As one of the most comprehensive educational meetings in the specialty, Fall Clinical is set to provide varying sessions blending emerging research with practical strategies to improve patient outcomes in 

In this year’s program, the conference is slated to have a variety of sessions, seminars-in-depth, and workshops spanning inflammatory and autoimmune skin disease, aesthetic dermatology, pigmentary conditions, and innovations in topical and systemic drugs. The 

 team will be attending the conference to deliver in-depth coverage of this meeting, including on-site interviews, session recaps, and key takeaways on recent data.

regarding insights from several sessions, including 

What Did 2025 Bring to the Table in Dermatology?”, “60 Tips for Better Outcomes: Aesthetic, Regenerative, Hair,” and “Seminar-in-Depth: The Reality of Actinic Keratosis: Centering Patient Experiences and Real-World Evidence

 Nestor will discuss real-world data shaping treatment approaches in aesthetic and regenerative dermatology and the evolving understanding of actinic keratosis management.

, will highlight advances in complex inflammatory skin disease and professional development, drawing from his roles in 

Seminar-in-Depth: Shifting the Management Paradigm in Generalized Pustular Psoriasis” and the “Early Career Dermatology Initiative (ECDI).

 His insights will address how new agents and evolving guidelines are influencing both practice and mentorship within the field.

, will discuss autoimmune blistering disease care following her presentation 

Seminar-in-Depth: Bullous Pemphigoid: The Time to Treat Is Now.

 She will highlight several points related to research and clinical pearls for bullous pemphigoid management.

What’s New in the Medicine Chest – Part 1


Presenter: James Q. Del Rosso, DO
Date/Time: Thursday, October 23 at 3:50 PM
Overview: A review of new systemic and topical agents entering dermatologic practice in 2025, highlighting pharmacologic mechanisms and pivotal trial data.

Seminar-in-Depth: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis


Presenter: James Q. Del Rosso, DO
Date/Time: Thursday, October 23 at 5:00 PM
Overview: A focused update on clinical evidence and therapeutic implications surrounding TYK2 inhibition as an emerging psoriasis treatment pathway.


Presenters: Boni E. Elewski, MD; Andrew F. Alexis, MD, MPH; Brad P. Glick, DO, MPH; Mark D. Kaufmann, MD; Peter A. Lio, MD; and E. James Song, MD
Date/Time: Friday, October 24 at 8:10 AM
Overview: Rapid-fire, evidence-based clinical pearls aimed at optimizing patient outcomes across dermatologic subspecialties.

What’s Itching You Today? Contact Derm? Atopic Derm? What Else?


Presenter: Shawn G. Kwatra, MD
Date/Time: Friday, October 24 at 11:35 AM
Overview: A practical discussion addressing diagnostic nuances and current management strategies in chronic pruritus, atopic dermatitis, and allergic contact dermatitis.

Mild to Moderate Atopic Dermatitis: Burden of Disease and a Topical Pathway for JAK Inhibition—Expert Therapeutic Update Session With Lunch


Presenter: Alexandra K. Golant, MD
Date/Time: Friday, October 24 at 12:45 PM
Overview: A sponsored educational session examining the burden of mild-to-moderate atopic dermatitis and the expanding role of topical JAK inhibitors in disease control.

The Changing Landscape of Topical Therapies


Presenters: Linda F. Stein Gold, MD; Cheri Frey, MD; Peter A. Lio, MD; and Bruce Strober, MD
Date/Time: Saturday, October 25 at 7:50 AM
Overview: A comprehensive overview of advances in topical therapy development, formulation science, and clinical integration across inflammatory and infectious dermatoses.

’s on-site coverage will provide daily highlights, exclusive interviews, and practical insights from Fall Clinical Dermatology 2025 in Las Vegas.
Stay tuned and check out the updated 

 for continuous developments covered throughout the meeting.

The 2025 Fall Clinical Dermatology Conference in Las Vegas will gather experts in medical, aesthetic, and surgical dermatology to share recent data and practical strategies for improving patient outcomes. The event will feature sessions on inflammatory and autoimmune skin diseases, aesthetic dermatology, and new drug innovations. Notable speakers include Mark Nestor, Raj Chovatiya, and Donna Culton, who will discuss real-world data, advances in inflammatory skin disease, and autoimmune blistering disease care. HCPLive will provide comprehensive coverage, including interviews and session recaps, to deliver key insights from the conference.

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Conference Preview: Fall Clinical Dermatology Conference 2025

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Antidepressants Differ Significantly in Cardiometabolic Side Effects 

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Dupilumab Reduces Mucus Burden in Uncontrolled Asthma, with Njira Lugogo, MD

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

Dyslipidemia

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Dyslipidemia May Delay Macular Hole Closure After Surgery

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.


Ustekinumab Linked to Lower 5-Year Cancer Risk vs Adalimumab in Psoriasis

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Pulmonary Fibrosis

From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD

This analysis highlights the impact of dermatology consultations on HS management within acute care settings.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology Consults Improve Follow-Up Care in Acute Care Management of HS

Insight into how response patterns from major studies help identify optimal treatment timing and predict which patients benefit most from specific interventions.

Video Series

Achieving Deeper Healing in Difficult-to-Treat Patients with IBD

Investigators estimate that replacing individually prescribed school-based devices with spare adrenaline autoinjectors could improve access for students.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Less Than Half of UK Students at Risk of Food Anaphylaxis Receive Epinephrine

Examination of how deeper healing correlates with improved long-term outcomes, emphasizing the translation of clinical trial findings into practical treatment adjustments.

Application of Response Trajectories to Treating Patients with IBD

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

Latest News

SELECT: Semaglutide Indicates Possible Cardiovascular Disease-Modifying Effect

Inside the FDA’s New Voucher Program: First 9 Picks Target Diabetes to Vaping

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD

Dupilumab Bests Omalizumab in Airway Improvement for Patients with CRSwNP and Asthma

Conference Preview: Fall Clinical Dermatology Conference 2025